

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JOINN LABORATORIES (CHINA) CO., LTD.**

### **北京昭衍新藥研究中心股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6127)**

### **VOLUNTARY ANNOUNCEMENT UNUSUAL PRICE MOVEMENT**

The board of directors (the “**Board**”) of JOINN Laboratories (China) Co., Ltd. (the “**Company**”) has noted unusual price movement of its shares in recent days.

The Board, having made such enquiries as are reasonable in the circumstances concerning the Company, confirms that, save as disclosed below, it is not aware of any reasons for the fluctuations in share price or trading volume, nor is it aware of any inside information that needs to be disclosed under Part XIVA of the Securities and Futures Ordinance.

Recently, the U.S. Food and Drug Administration (FDA) announced a scheme (the “**Scheme**”) that may cause fluctuations in the price of the Company’s shares. The Scheme calls for the elimination of animal testing of monoclonal antibodies and other drugs. The Company has been engaged in the field of non-clinical drug research for 30 years. It always keeps pace with the development of the industry, continuously innovates and researches and develops, and is committed to providing customers with high-quality technical services. The Company strictly follows the “3R” principle of animal experiments, namely “Reduction”, “Refinement” and “Replacement”, and has been making continuous efforts in animal testing and animal welfare. In recent years, the Company has continuously focused on and strengthened the development of organoid research, hoping that in vitro testing can replace live animal research testing as soon as possible. The Company believes that the Scheme will be gradually implemented based on solid scientific data research, pushing the industry to accelerate the pace of alternative research. This development direction is consistent with the Company’s service purpose and development plan. In the future, the Company will continue to be committed to relevant research and contribute to promoting sustainable development in the field of pharmaceutical research and development.

By order of the Board  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Beijing, the PRC, 11 April 2025

*As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Gao Dapeng, Ms. Sun Yunxia, Ms. Luo Xi and Mr. Gu Jingliang as executive Directors, and Mr. Zhang Fan, Mr. Yang Fuquan, Mr. Yang Changyun and Mr. Ying Fangtian as independent non-executive Directors.*